# OnCo record paper-nct02107703-jama-oncol-2020-update (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct02107703-jama-oncol-2020-update/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct02107703-jama-oncol-2020-update" ;
  schema:name "The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial"@en ;
  schema:description "Later report from the MONARCH 2 trial registered as NCT02107703, in JAMA Oncology (2020); its title describes an updated or longer-term analysis."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct02107703-jama-oncol-2020-update/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2019.4782>, <https://pubmed.ncbi.nlm.nih.gov/31563959/>, <https://europepmc.org/article/MED/31563959>, <https://clinicaltrials.gov/study/NCT02107703> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2019.4782> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Sledge GW, Toi M, Neven P, et al." ;
  onco:trials <https://onco.cc/trials/nct02107703/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .